Medication Management and Medication-Related Problems in People with Chronic Liver Disease
Not Applicable
Completed
- Conditions
- Decompensated liver cirrhosisOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
- Registration Number
- ACTRN12616000780459
- Lead Sponsor
- The University of Queensland
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Eligible participants will be adults aged 18 years or older with cirrhosis and current or previous chronic liver failure (CLF)-related complication(s), including ascites, variceal bleeding, spontaneous bacterial peritonitis, sepsis, encephalopathy, liver cancer or liver-related renal dysfunction.
Exclusion Criteria
Exclusion criteria will include inability to provide informed consent and intensive management by other health care teams (i.e. liver transplant team, palliative care).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A composite endpoint of frequency (counts of) and severity (measure of clinical significance) of discrepancies between patient-reported and clinician-documented 'current' medications. Discrepancies (between medication names, doses and frequency of administration) will be documented during face-to-face and telephone interviews at week 0, 4, 13 and 26 (week 0 and 26 only for ‘standard care’ participants). The clinical significance of discrepancies will be determined by a panel (including a hepatologist, pharmacist, pharmacologist and nurse). Data will be presented both qualitatively (description of high-risk discrepancies) and quantitatively (chi-square / Fisher's exact test for statistically significant differences between intervention and control groups at baseline and 6 months).[Discrepancies present at baseline vs. at 6 months. ]
- Secondary Outcome Measures
Name Time Method